E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
mycosis fungoides |
Mycosis Fungoides |
|
E.1.1.1 | Medical condition in easily understood language |
kind of skin cancer |
Form von Hautkrebs |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10028503 |
E.1.2 | Term | Mycosis fungoides stage I |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10028504 |
E.1.2 | Term | Mycosis fungoides stage II |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine whether PUVA maintenance therapy does prolong disease free survival after initial complete response. |
Es soll untersucht werden, ob die Erhaltungstherapie das Auftreten des Rezidivs verhindert bzw. das Zeitintervall bis zum Auftreten des Rezidivs verlängert.
|
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Histopathologically documented MF clinical stage IA-IIB (see Table1) confirmed by current or previous diagnostic lesion biopsy
• A Karnofsky performance score > 60 (see Table 2)
• Age > 18 years - ≤ 85
• Anti-ds-DNA (antinuclear antibodies) AND anti-Ro/La antibodies: negative
• Acceptable organ function defined as follows:
SGOT (AST) and SGPT (ALT) < 2.5 times the upper limit of normal for the institution
• Creatinine < 2 times the upper limit of normal for the institution
• No evidence of severe cardiac insufficiency (NYHA grade III-IV)
• Women of child bearing potential must have a negative serum or urine pregnancy test (ß-HCG) within seven (7) days prior to randomization
• Absence of any serious intercurrent illness or infection at time of entry into the study that could interfere with planned treatment
• Patients must be willing to accept limiting sun exposure on the day receiving PUVA treatment
• Written informed consent
|
|
E.4 | Principal exclusion criteria |
• Pregnancy and Lactation
• Photosensitive diseases such as lupus erythematosus or basal cell nevus syndrome
• Skin cancer syndromes such as Xeroderma pigmentosum or basal cell nevus syndrome
• PUVA (oral or topical) treatment within the last 3 months
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Comparison of median time to recurrence after complete remission between patients treated with maintenance therapy vs. patients without maintenance therapy. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
timepoint: up to five years after the end of treatment |
|
E.5.2 | Secondary end point(s) |
Comparison of time from end of treatment to recurrence on condition that the patient is in complete remission at the end of treatment between patients treated with maintenance therapy vs. patients without maintenance therapy.
- Cytokine response in serum and tissue
- Quality of life
- HADS
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Comparison of time from end of treatment to recurrence on condition that the patient is in complete remission at the end of treatment between patients treated with maintenance therapy vs. patients without maintenance therapy.
Cytokine response in serum and tissue:
before start of treatment, week 6 and 12 and two optional timepoints. During maintenance therapy: week 24 and end of maintenance therapy
Quality of life and HADS: each follow-up exam
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 10 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 6 |
E.8.9.1 | In the Member State concerned months | 3 |
E.8.9.1 | In the Member State concerned days | 0 |